SAN DIEGO--(BUSINESS WIRE)--Illumina, Inc. (NASDAQ:ILMN) today launched its real-time PCR reagent portfolio, including a novel, probe-based chemistry for gene expression analysis called NuPCR™. In addition to the NuPCR Reagents, Illumina announced qPCR DNA Binding Dye (DBD) Assays for Gene Expression Analysis and qPCR High Resolution Melting (HRM) Assays for genotyping studies, providing researchers with a trio of high-quality, budget-friendly options in the qPCR reagent market.
